MicroRNA expression and gene regulation drive breast cancer progression and metastasis in PyMT mice

Rubén Nogales‐Cadenas, Ying Cai, Jhih‐Rong Lin, Quanwei Zhang, Wen Zhang, Cristina Montagna, Zhengdong D. ZhangBreast 2016 · DOI

TL;DR

This study investigates the role of microRNAs (miRNAs) in driving breast cancer progression and metastasis using a mouse model. By integrating miRNA and messenger RNA (mRNA) expression data across different stages of tumor development, the researchers identified key regulatory networks and novel functional programs that contribute to cancer hallmarks like invasion and metastasis.

What Problem Does This Paper Address?

Breast cancer is a complex disease with various subtypes, and understanding the molecular mechanisms driving its progression and metastasis is crucial for developing effective treatments. Luminal B breast cancer, a common but less-studied subtype, presents a particular challenge. While microRNAs (miRNAs) are known to be critical regulators of cellular processes and are implicated in cancer, their specific roles in the multi-stage progression of luminal B breast cancer, especially in driving metastasis, remain largely unexplored. This paper aims to fill this knowledge gap by comprehensively profiling miRNA and mRNA expression in a well-established mouse model of luminal B breast cancer (PyMT mice) across different stages of tumor development.

Methods

The researchers employed a multi-omics approach, integrating small RNA sequencing (RNA-seq) for miRNA profiling and RNA-seq for mRNA profiling. They analyzed samples from PyMT mice at four distinct time points representing different stages of cancer progression (hyperplasia, adenoma/MIN, early carcinoma, and late carcinoma with metastasis).

Key methodological innovations include:

  • Tripartite Network Construction: They built a novel "PyMT-specific tripartite miRNA-mRNA-pathway network." This network integrates miRNA expression, mRNA expression, and functional/pathway annotations of genes.
  • Novel Clustering Method for Functional Regulatory Programs (FRPs): To identify biologically meaningful modules within the complex networks, they developed and applied a novel clustering method. This involved identifying maximal bicliques (MBs) within the annotated mRNA-pathway networks and then adding the relevant miRNAs to form FRPs. This approach aimed to overcome limitations of standard clustering methods when dealing with dense networks.
  • Integration with Existing Databases: They leveraged existing databases like m3RNA for miRNA-mRNA interactions and CancerMiner for validating predicted interactions with human cancer data.

Datasets

  • PyMT Mouse Model Data: The primary dataset consists of miRNA and mRNA expression profiles from mammary tumors and normal mammary glands of PyMT mice at four distinct time points (weeks 6, 8, 10, and 12). This dataset includes 24 samples in total (3 tumor and 3 normal samples per time point).
  • External Databases:
    • miRBase: Used for identifying transcribed miRNAs.
  • m3RNA Database: Provided a large set of potential miRNA-mRNA interactions.
  • CancerMiner: Used to validate predicted miRNA-mRNA interactions against human cancer data.
  • Gene Ontology (GO), KEGG, and Panther Pathways: Used for functional and pathway enrichment analysis of genes.
  • TCGA Dataset: Used to study the expression profiles of specific genes across human breast cancer subtypes.

Key Insights and Ideas

  • Dual Nature of miRNAs: A significant finding is that 151 differentially expressed miRNAs exhibited a "strict dual nature," meaning they were consistently upregulated or downregulated throughout the entire progression of breast cancer. This suggests a complex regulatory role where miRNAs act as either promoters or suppressors of tumor development.
  • Novel miRNAs in Cancer Progression: The study identified 82 "novel" breast-cancer-related miRNAs (not previously known to play a role in breast cancer). This expands the known repertoire of miRNAs involved in this disease.
  • miRNA-Driven Hallmarks of Cancer: The research directly links miRNA activity to specific "hallmarks of cancer," particularly highlighting their role in activating invasion and metastasis, sustaining proliferative signaling, and evading growth suppressors. This provides a mechanistic understanding of how miRNAs contribute to aggressive tumor behavior.
  • Dynamic Regulation Across Stages: The study emphasizes that miRNA regulatory activity is not static but changes dynamically across different stages of cancer progression, with some processes being more active in early stages (e.g., angiogenesis) and others in later stages (e.g., invasion and metastasis).
  • Fatty Acid Metabolism as a Key Target: The paper identifies fatty acid metabolism as a particularly active area of miRNA regulation during tumor progression, linking it to energy storage, membrane proliferation, and signaling molecules crucial for cancer growth.

Key Results

  • 151 Differentially Expressed miRNAs: Identified 151 miRNAs with significant differential expression between tumor and normal samples across the four time points.
  • 82 Novel Breast Cancer miRNAs: Discovered 82 miRNAs not previously implicated in breast cancer.
  • 35 Novel miRNAs Regulate 271 Genes: Identified 35 of these novel miRNAs as potentially regulating 271 protein-coding genes based on sequence complementarity and expression profiles.
  • Validation of Interactions: Approximately 60% of predicted miRNA-mRNA pairs in the PyMT model were consistent with interactions validated in human cancers, increasing to nearly 100% when considering interactions found in at least one human cancer type.
  • Identification of 84 Functional Regulatory Programs (FRPs): The novel clustering method identified 84 FRPs involved in various cancer-related biological processes.
  • Specific Gene Regulation: Highlighted specific miRNAs (e.g., miR-143, miR-27b, miR-141, miR-200a, miR-148a) regulating key genes involved in fatty acid metabolism (e.g., PPARA, PPARG, OLR1, FAAH).

Limitations and Future Work

  • Mouse Model vs. Human Cancer: While the PyMT model closely resembles luminal B breast cancer, it has limitations in fully recapitulating all aspects of human breast cancer development. The authors acknowledge that transgene expression levels and cell-type specificity might differ from human scenarios.
  • Computational Predictions: While efforts were made to validate predicted miRNA-mRNA interactions, the study relies on computational predictions, which inherently have a degree of uncertainty.
  • Future Work: The authors suggest that the identified novel miRNAs and FRPs could serve as potential biomarkers for early cancer detection and as targets for developing new therapeutic strategies. Further experimental validation of these findings in human breast cancer contexts is warranted. The study also opens avenues for exploring the specific roles of identified miRNAs in processes like angiogenesis, cell adhesion, and metabolism in more detail.

Summary updated

Abstract

In this study we profiled the expression of miRNAs during breast cancer progression in the PyMT mouse model. By integrating miRNA and mRNA expression profiles, we identified differentially expressed miRNAs and their target genes involved in several hallmarks of cancer. We applied a novel clustering method to an annotated miRNA-mRNA regulatory network and identified network modules involved in specific cancer-related biological processes.
BibTeX
@inproceedings{nogalescadenas2016microrna,
  author = {Rubén Nogales‐Cadenas and Ying Cai and Jhih‐Rong Lin and Quanwei Zhang and Wen Zhang and Cristina Montagna and Zhengdong D. Zhang},
  title = {{MicroRNA expression and gene regulation drive breast cancer progression and metastasis in PyMT mice}},
  booktitle = {Breast},
  year = {2016},
  doi = {10.1186/s13058-016-0735-z},
}
Figure